# A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP

> **NCT07702851** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Yonsei University** · enrollment: 47 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Polatuzumab vedotin, Glofitamab

## Key facts

- **NCT ID:** NCT07702851
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2030-08-31
- **Final completion:** 2030-08-31
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2026-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07702851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07702851, "A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07702851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*